Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNX-601 ER Monotherapy in Major Depressive Disorder
NCT05686408Phase 2Completed
- Sponsor
- Tonix Pharmaceuticals
- Start
- Mar 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tianeptine hemioxalate in major depressive disorder (MDD), sponsored by Tonix Pharmaceuticals. Started Mar 2023; status: completed.
02
Drugs
tianeptine hemioxalate
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05686408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05686408.